Predicted protein targets (top 2)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SELE | P16581 | 15/20 | 0.62 |
| ▸ | STAT3 | P40763 | 5/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11962146 | 0.91 | SELE (0.66) | SELESTAT3 | |
| SCHEMBL9613573 | 0.90 | SELE (0.64) | SELESTAT3 | |
| SCHEMBL12257332 | 0.87 | SELE (0.65) | SELE | |
| SCHEMBL12257310 | 0.85 | SELE (0.77) | SELESTAT3 | |
| SCHEMBL12909330 | 0.81 | SELE (0.48) | SELESTAT3 | |
| SCHEMBL14096760 | 0.81 | SELE (0.47) | SELESTAT3 | |
| SCHEMBL11982132 | 0.81 | SELE (0.70) | SELE | |
| SCHEMBL11962140 | 0.80 | SELE (0.68) | SELE | |
| SCHEMBL11962133 | 0.80 | SELE (0.82) | SELESTAT3 | |
| SCHEMBL9613593 | 0.79 | SELE (0.66) | SELE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8026222-B2 | Use of oligosaccharide compound or glycomimetic compound wherein a cyclohexane derivative is incorporated therein; treating inflammatory, vascular, and skin disorders such as diabetes, atherosclerosis, dermatitis, graft versus host disease, and lymphomas | GLYCOMIMETICS, INC. (US) | 2011-09-27 | — | — | US | disclosed |
| US-7964569-B2 | Oligosaccharide mimetics such as {(1R,2R,3S)-2-[(6-Deoxy- alpha -L-Galactopyranosyl)Oxy]-3-Ethyl-Cyclohex-1-yl}2-O-Benzoyl-3-O-[(1S)-1-Carboxy-2-Cyclohexyl-Ethyl]- beta -D-Galactopyranoside | GLYCOMIMETICS, INC. (US) | 2011-06-21 | — | — | US | disclosed |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | GLYCOMIMETICS, INC. (US) | 2008-07-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080161546-A1 | Glycomimetic replacements for hexoses and N-acetyl hexosamines | FUT6, B3GNT2, FUT5 | SELE 622/4885STAT3 4744/4885 |
| US-20080200406-A1 | Methods of use of glycomimetics with replacements for hexoses and n-acetyl hexosamines | FUT6, ENGASE, FUT5 | SELE 158/4885STAT3 4838/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.